Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2)

Volker Möbus,Hans-Joachim Lück,Ekkehart Ladda,Peter Klare,Marcus Schmidt, Andreas Schneeweiss,Eva-Maria Grischke,Grischa Wachsmann,Helmut Forstbauer,Michael Untch,Frederik Marmé, Jens-Uwe Blohmer,Christian Jackisch,Jens Huober, Elmar Stickeler,Mattea Reinisch,Theresa Link,Bruno V Sinn, Wolfgang Janni,Carsten Denkert,Jenny Furlanetto,Knut Engels,Christine Solbach,Sabine Schmatloch,Julia Rey,Nicole Burchardi,Sibylle Loibl

European Journal of Cancer（2021）

引用 5|浏览22

暂无评分

摘要

•Adjuvant intense dose-dense regimens and survival in high-risk breast cancer.•Tailored dose-dense compared with specified dose-dense regimens in high-risk BC.•Tailored dose-dense regimen is superior in luminalB, lobular cancer and ≤50 years.•Toxicity and different intense dose-dense regimens.•GAIN-2 results support increasing the dose intensity.

查看译文

关键词

Early breast cancer,Adjuvant chemotherapy,Dose-dense chemotherapy,Randomised trial

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要